RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GeneFerm Biotechnology Co Stock

GeneFerm Biotechnology Co Liabilities 2024

GeneFerm Biotechnology Co Liabilities

282.54 M TWD

Ticker

1796.TWO

ISIN

TW0001796001

In 2024, GeneFerm Biotechnology Co's total liabilities amounted to 282.54 M TWD, a -21.27% difference from the 358.86 M TWD total liabilities in the previous year.

GeneFerm Biotechnology Co Aktienanalyse

What does GeneFerm Biotechnology Co do?

GeneFerm Biotechnology Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing GeneFerm Biotechnology Co's Liabilities

GeneFerm Biotechnology Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating GeneFerm Biotechnology Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing GeneFerm Biotechnology Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

GeneFerm Biotechnology Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in GeneFerm Biotechnology Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about GeneFerm Biotechnology Co stock

What is the level of liabilities of GeneFerm Biotechnology Co this year?

GeneFerm Biotechnology Co has a debt balance of 282.54 M TWD this year.

What were the liabilities of GeneFerm Biotechnology Co compared to the previous year?

The liabilities of GeneFerm Biotechnology Co have increased by -21.27% dropped compared to the previous year.

What are the consequences of high debt for investors of GeneFerm Biotechnology Co?

High liabilities can pose a risk for investors of GeneFerm Biotechnology Co, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in GeneFerm Biotechnology Co?

Low liabilities mean that GeneFerm Biotechnology Co has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of GeneFerm Biotechnology Co affect the company?

An increase in liabilities of GeneFerm Biotechnology Co can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of GeneFerm Biotechnology Co affect the company?

A decrease in the liabilities of GeneFerm Biotechnology Co can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of GeneFerm Biotechnology Co?

Some factors that can influence the liabilities of GeneFerm Biotechnology Co include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of GeneFerm Biotechnology Co so important for investors?

The liabilities of GeneFerm Biotechnology Co are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can GeneFerm Biotechnology Co take to modify the liabilities?

To change its liabilities, GeneFerm Biotechnology Co can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does GeneFerm Biotechnology Co pay?

Over the past 12 months, GeneFerm Biotechnology Co paid a dividend of 1.5 TWD . This corresponds to a dividend yield of about 3.15 %. For the coming 12 months, GeneFerm Biotechnology Co is expected to pay a dividend of 1.5 TWD.

What is the dividend yield of GeneFerm Biotechnology Co?

The current dividend yield of GeneFerm Biotechnology Co is 3.15 %.

When does GeneFerm Biotechnology Co pay dividends?

GeneFerm Biotechnology Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of GeneFerm Biotechnology Co?

GeneFerm Biotechnology Co paid dividends every year for the past 2 years.

What is the dividend of GeneFerm Biotechnology Co?

For the upcoming 12 months, dividends amounting to 1.5 TWD are expected. This corresponds to a dividend yield of 3.15 %.

In which sector is GeneFerm Biotechnology Co located?

GeneFerm Biotechnology Co is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von GeneFerm Biotechnology Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GeneFerm Biotechnology Co from 7/31/2024 amounting to 2 TWD, you needed to have the stock in your portfolio before the ex-date on 7/10/2024.

When did GeneFerm Biotechnology Co pay the last dividend?

The last dividend was paid out on 7/31/2024.

What was the dividend of GeneFerm Biotechnology Co in the year 2023?

In the year 2023, GeneFerm Biotechnology Co distributed 1 TWD as dividends.

In which currency does GeneFerm Biotechnology Co pay out the dividend?

The dividends of GeneFerm Biotechnology Co are distributed in TWD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von GeneFerm Biotechnology Co

Our stock analysis for GeneFerm Biotechnology Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GeneFerm Biotechnology Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.